Cargando…
The Prognostic Value and Clinical Use of Myocardial Perfusion Scintigraphy in Asymptomatic Patients after Percutaneous Coronary Intervention
BACKGROUND: The role of myocardial perfusion scintigraphy (MPS) in the follow-up of asymptomatic patients after percutaneous coronary intervention (PCI) is not established. OBJECTIVES: To evaluate the prognostic value and clinical use of MPS in asymptomatic patients after PCI. METHODS: Patients who...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Sociedade Brasileira de Cardiologia - SBC
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6263458/ https://www.ncbi.nlm.nih.gov/pubmed/30517374 http://dx.doi.org/10.5935/abc.20180199 |
_version_ | 1783375297952874496 |
---|---|
author | de Andrade, Larissa Franco Souza, Ana Carolina Peclat, Thais Bartholo, Caio Pavanelo, Thalita Lima, Ronaldo de Souza Leão |
author_facet | de Andrade, Larissa Franco Souza, Ana Carolina Peclat, Thais Bartholo, Caio Pavanelo, Thalita Lima, Ronaldo de Souza Leão |
author_sort | de Andrade, Larissa Franco |
collection | PubMed |
description | BACKGROUND: The role of myocardial perfusion scintigraphy (MPS) in the follow-up of asymptomatic patients after percutaneous coronary intervention (PCI) is not established. OBJECTIVES: To evaluate the prognostic value and clinical use of MPS in asymptomatic patients after PCI. METHODS: Patients who underwent MPS consecutively between 2008 and 2012 after PCI were selected. The MPS were classified as normal and abnormal, the perfusion scores, summed stress score (SSS), and summed difference score (SDS) were calculated and converted into percentage of total perfusion defect and ischemic defect. The follow-up was undertaken through telephone interviews and consultation with the Mortality Information System. Primary endpoints were death, cardiovascular death, and nonfatal acute myocardial infarction (AMI), and secondary endpoint was revascularization. Logistic regression and COX method were used to identify the predictors of events, and the value of p < 0.05 was considered statistically significant. RESULTS: A total of 647 patients were followed for 5.2 ± 1.6 years. 47% of MPS were normal, 30% were abnormal with ischemia, and 23% were abnormal without ischemia. There were 61 deaths, 27 being cardiovascular, 19 non-fatal AMI, and 139 revascularizations. The annual death rate was higher in those with abnormal perfusion without ischemia compared to the groups with ischemia and normal perfusion (3.3% × 2% × 1.2%, p = 0.021). The annual revascularization rate was 10.3% in the ischemia group, 3.7% in those with normal MPS, and 3% in those with abnormal MPS without ischemia. The independent predictors of mortality and revascularization were, respectively, total perfusion defect greater than 6%, and ischemic defect greater than 3%. Forty-two percent of the patients underwent MPS less than 2 years after PCI, and no significant differences were observed in relation to those who underwent it after that period. CONCLUSION: Although this information is not contemplated in guidelines, in this study MPS was able to predict events in asymptomatic after PCI patients, regardless of when they were performed. |
format | Online Article Text |
id | pubmed-6263458 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Sociedade Brasileira de Cardiologia - SBC |
record_format | MEDLINE/PubMed |
spelling | pubmed-62634582018-12-05 The Prognostic Value and Clinical Use of Myocardial Perfusion Scintigraphy in Asymptomatic Patients after Percutaneous Coronary Intervention de Andrade, Larissa Franco Souza, Ana Carolina Peclat, Thais Bartholo, Caio Pavanelo, Thalita Lima, Ronaldo de Souza Leão Arq Bras Cardiol Original Article BACKGROUND: The role of myocardial perfusion scintigraphy (MPS) in the follow-up of asymptomatic patients after percutaneous coronary intervention (PCI) is not established. OBJECTIVES: To evaluate the prognostic value and clinical use of MPS in asymptomatic patients after PCI. METHODS: Patients who underwent MPS consecutively between 2008 and 2012 after PCI were selected. The MPS were classified as normal and abnormal, the perfusion scores, summed stress score (SSS), and summed difference score (SDS) were calculated and converted into percentage of total perfusion defect and ischemic defect. The follow-up was undertaken through telephone interviews and consultation with the Mortality Information System. Primary endpoints were death, cardiovascular death, and nonfatal acute myocardial infarction (AMI), and secondary endpoint was revascularization. Logistic regression and COX method were used to identify the predictors of events, and the value of p < 0.05 was considered statistically significant. RESULTS: A total of 647 patients were followed for 5.2 ± 1.6 years. 47% of MPS were normal, 30% were abnormal with ischemia, and 23% were abnormal without ischemia. There were 61 deaths, 27 being cardiovascular, 19 non-fatal AMI, and 139 revascularizations. The annual death rate was higher in those with abnormal perfusion without ischemia compared to the groups with ischemia and normal perfusion (3.3% × 2% × 1.2%, p = 0.021). The annual revascularization rate was 10.3% in the ischemia group, 3.7% in those with normal MPS, and 3% in those with abnormal MPS without ischemia. The independent predictors of mortality and revascularization were, respectively, total perfusion defect greater than 6%, and ischemic defect greater than 3%. Forty-two percent of the patients underwent MPS less than 2 years after PCI, and no significant differences were observed in relation to those who underwent it after that period. CONCLUSION: Although this information is not contemplated in guidelines, in this study MPS was able to predict events in asymptomatic after PCI patients, regardless of when they were performed. Sociedade Brasileira de Cardiologia - SBC 2018-12 /pmc/articles/PMC6263458/ /pubmed/30517374 http://dx.doi.org/10.5935/abc.20180199 Text en http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article de Andrade, Larissa Franco Souza, Ana Carolina Peclat, Thais Bartholo, Caio Pavanelo, Thalita Lima, Ronaldo de Souza Leão The Prognostic Value and Clinical Use of Myocardial Perfusion Scintigraphy in Asymptomatic Patients after Percutaneous Coronary Intervention |
title | The Prognostic Value and Clinical Use of Myocardial Perfusion
Scintigraphy in Asymptomatic Patients after Percutaneous Coronary
Intervention |
title_full | The Prognostic Value and Clinical Use of Myocardial Perfusion
Scintigraphy in Asymptomatic Patients after Percutaneous Coronary
Intervention |
title_fullStr | The Prognostic Value and Clinical Use of Myocardial Perfusion
Scintigraphy in Asymptomatic Patients after Percutaneous Coronary
Intervention |
title_full_unstemmed | The Prognostic Value and Clinical Use of Myocardial Perfusion
Scintigraphy in Asymptomatic Patients after Percutaneous Coronary
Intervention |
title_short | The Prognostic Value and Clinical Use of Myocardial Perfusion
Scintigraphy in Asymptomatic Patients after Percutaneous Coronary
Intervention |
title_sort | prognostic value and clinical use of myocardial perfusion
scintigraphy in asymptomatic patients after percutaneous coronary
intervention |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6263458/ https://www.ncbi.nlm.nih.gov/pubmed/30517374 http://dx.doi.org/10.5935/abc.20180199 |
work_keys_str_mv | AT deandradelarissafranco theprognosticvalueandclinicaluseofmyocardialperfusionscintigraphyinasymptomaticpatientsafterpercutaneouscoronaryintervention AT souzaanacarolina theprognosticvalueandclinicaluseofmyocardialperfusionscintigraphyinasymptomaticpatientsafterpercutaneouscoronaryintervention AT peclatthais theprognosticvalueandclinicaluseofmyocardialperfusionscintigraphyinasymptomaticpatientsafterpercutaneouscoronaryintervention AT bartholocaio theprognosticvalueandclinicaluseofmyocardialperfusionscintigraphyinasymptomaticpatientsafterpercutaneouscoronaryintervention AT pavanelothalita theprognosticvalueandclinicaluseofmyocardialperfusionscintigraphyinasymptomaticpatientsafterpercutaneouscoronaryintervention AT limaronaldodesouzaleao theprognosticvalueandclinicaluseofmyocardialperfusionscintigraphyinasymptomaticpatientsafterpercutaneouscoronaryintervention AT deandradelarissafranco prognosticvalueandclinicaluseofmyocardialperfusionscintigraphyinasymptomaticpatientsafterpercutaneouscoronaryintervention AT souzaanacarolina prognosticvalueandclinicaluseofmyocardialperfusionscintigraphyinasymptomaticpatientsafterpercutaneouscoronaryintervention AT peclatthais prognosticvalueandclinicaluseofmyocardialperfusionscintigraphyinasymptomaticpatientsafterpercutaneouscoronaryintervention AT bartholocaio prognosticvalueandclinicaluseofmyocardialperfusionscintigraphyinasymptomaticpatientsafterpercutaneouscoronaryintervention AT pavanelothalita prognosticvalueandclinicaluseofmyocardialperfusionscintigraphyinasymptomaticpatientsafterpercutaneouscoronaryintervention AT limaronaldodesouzaleao prognosticvalueandclinicaluseofmyocardialperfusionscintigraphyinasymptomaticpatientsafterpercutaneouscoronaryintervention |